IGC Pharma Inc Stock Price, News & Analysis

IGC Pharma (NYSE American: IGC) held its Annual Meeting on October 10, 2025 where stockholders approved all proposals disclosed in the Definitive Proxy on Schedule 14A dated August 18, 2025.

Approved actions include: (i) election of Ram Mukunda and James Moran as Class C directors through the 2028 annual meeting; (ii) ratification of Manohar Chowdhry & Associates as independent registered public accounting firm for fiscal 2026; (iii) authorization to grant 5,000,000 shares of common stock to employees, advisors, directors, and consultants under board/CEO-set metrics; and (iv) amendment to increase authorized common shares from 150,000,000 to 600,000,000.

IGC (NYSE American: IGC) announced preclinical in-vitro data for IGC-1C on October 7, 2025, describing a novel approach that targets tau protein liquid-liquid phase separation (LLPS).

Key findings include inhibition and dissolution of zinc-mediated tau condensates, reduction in condensate size and number, prevention of conversion to amyloid fibrils, and a measured tau binding affinity of Kd 3.95 ± 0.32 μM. IGC-1C was permeable and well tolerated in SH-SY5Y cell cultures. The company plans additional animal validation studies with the stated goal of advancing IGC-1C toward clinical trials.

IGC Pharma (NYSE American: IGC) announced the addition of Ichor Research in Syracuse, New York, as a new clinical trial site for its ongoing Phase 2 CALMA trial. The study evaluates IGC-AD1, an investigational drug candidate for treating agitation in Alzheimer's disease patients.

The trial, designed as a randomized, double-blind, placebo-controlled study, will be led by Principal Investigator Dr. Karl F. Hafner, M.D. at the new site. The CALMA trial aims to assess the safety and efficacy of IGC-AD1 in reducing agitation symptoms, which are among the most common and distressing behavioral symptoms in Alzheimer's patients.

IGC Pharma (NYSE American:IGC) has announced promising preclinical data for its Alzheimer's disease candidate TGR-63. The research reveals TGR-63's dual mechanism of action, demonstrating its ability to target both beta-amyloid (Aβ) plaques and tau protein aggregation, two major hallmarks of Alzheimer's disease.

The studies showed that TGR-63 suppresses tau fibril formation at micromolar concentrations and maintains structural stability under physiological conditions. MALDI mass spectrometry detected the compound in serum samples at both 1- and 24-hours post-administration, indicating strong pharmacological resilience and systemic delivery potential.

IGC Pharma (NYSE American:IGC) has achieved 50% enrollment in its Phase 2 CALMA clinical trial for IGC-AD1, a treatment targeting agitation in Alzheimer's disease. The trial is a multicenter, double-blind, placebo-controlled, randomized study evaluating their proprietary formulation that combines low-dose THC with another active pharmaceutical ingredient.

The company has expanded its trial network to include six new research sites across Florida, Ontario, Rhode Island, Oklahoma, British Columbia, and Puerto Rico. IGC-AD1 shows promise through its multi-modal mechanism of action, potentially addressing both agitation symptoms and disease modification. Based on encouraging Phase 1 data and interim Phase 2 analysis, the company expects to complete the trial in early 2026.

IGC Pharma (NYSE American:IGC), a clinical-stage pharmaceutical company, has received its third award from the National Institute on Aging (NIA) for excellence in AI code development as part of the PREPARE Challenge. The company's AI team was recognized for developing well-structured and transparent code for Alzheimer's detection.

The team created a multilingual AI model using DementiaBank data to detect acoustic biomarkers linked to early cognitive decline. The company's AI initiatives include MINT-AD, an advanced platform integrating multiple biomarkers for individualized Alzheimer's disease forecasting. Previously, IGC received the Disproportionate Impact Award, third place in Phase 1, and a prize for generalization in Phase 2 of the PREPARE Challenge.

IGC Pharma (NYSE American:IGC) announced the expansion of its Phase 2 CALMA clinical trial for IGC-AD1, a novel treatment for agitation in Alzheimer's dementia, to Island Health's Royal Jubilee Hospital in Victoria, British Columbia, Canada.

The CALMA trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of IGC-AD1 in managing agitation in Alzheimer's patients. This expansion strengthens the trial's clinical infrastructure across North America and aims to increase access for patients and caregivers while supporting timely enrollment towards trial completion.

IGC Pharma (NYSE American:IGC) has received a Notice of Allowance from the USPTO for patent application US 17/613,909 (IGC510), covering a novel treatment method using THC and/or CBD for stammering, stuttering, and Tourette's syndrome. The therapeutic approach combines microdoses of THC with atypical antipsychotics to target the endocannabinoid system.

The treatment aims to serve an estimated 75 million people globally affected by these conditions. The patent adds to IGC's portfolio, which includes treatments for Alzheimer's, pain, and eating disorders. The company plans to develop clinical formulations similar to their flagship medication IGC-AD1, currently in Phase 2 CALMA clinical trials.

IGC Pharma (NYSE American:IGC) announced that Ascendiant Capital Markets has released a new coverage report on the company. The report raises the price target to $4.50 and suggests that upcoming clinical data and progress in 2025 could serve as strong catalysts for the stock.

The company explicitly stated that analyst views represent their independent opinions and that IGC Pharma is not responsible for the content, accuracy, or timelines provided in such reports.